To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

Nanjing University School of Medicine

Status and phase

Completed

Phase 4

Conditions

Membranous Nephropathy

Treatments

Drug: TW

Study type

Interventional

Funder types

Other

Identifiers

NCT00518219

NJCT-0702

Details and patient eligibility

About

The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.

Full description

Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.

Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.

Enrollment

68 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Biopsy-proven idiopathic membranous nephropathy
Nephrotic syndrome with proteinuria (> 4 g/day) and serum albumin < 30 g/dl
Age over 18 with informed consent

Exclusion criteria

Patient with abnormal liver function tests
Prior therapy with sirolimus, CSA, MMF, tacrolimus or azathioprin, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days,
Active/serious infection,
Patient with hepatitis B surface antigen or who is hepatitis C antibody positive